EP2941424A1 - 1,2,3-triazol-4-amin-derivate zur behandlung von sigma-rezeptor-vermittelten erkrankungen und störungen - Google Patents

1,2,3-triazol-4-amin-derivate zur behandlung von sigma-rezeptor-vermittelten erkrankungen und störungen

Info

Publication number
EP2941424A1
EP2941424A1 EP14700430.3A EP14700430A EP2941424A1 EP 2941424 A1 EP2941424 A1 EP 2941424A1 EP 14700430 A EP14700430 A EP 14700430A EP 2941424 A1 EP2941424 A1 EP 2941424A1
Authority
EP
European Patent Office
Prior art keywords
substituted
unsubstituted
group
mono
polycyclic ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP14700430.3A
Other languages
English (en)
French (fr)
Other versions
EP2941424B1 (de
Inventor
Antoni Torrens-Jover
Ute Christmann
José-Luis Diaz-Fernandez
Carmen ALMANSA-ROSALES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Priority to EP14700430.3A priority Critical patent/EP2941424B1/de
Publication of EP2941424A1 publication Critical patent/EP2941424A1/de
Application granted granted Critical
Publication of EP2941424B1 publication Critical patent/EP2941424B1/de
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage

Definitions

  • sigma receptors include cell surface receptors of the central nervous system (CNS) which may be related to the dysphoric, hallucinogenic and cardiac stimulant effects of opioids.
  • CNS central nervous system
  • sigma receptor ligands may be useful in the treatment of psychosis and movement disorders such as dystonia and tardive dyskinesia, and motor disturbances associated with Huntington's chorea or Tourette's syndrome and in Parkinson's disease ( Walker, J.M. et al, Pharmacological Reviews, 1990, 42, 355).
  • sigma receptor(s) refers to proteinaceous molecules, containing (a) binding site(s), which molecules functionally differ from opioid, NMDA, dopaminergic, and other known neurotransmitter or hormone receptor families (G. Ronsisvalle et al. Pure Appl. Chem. 73, 1499-1509 (2001 )).
  • the sigma receptor has at least two subtypes, which may be discriminated by stereoselective isomers of pharmacoactive drugs.
  • SKF 10047 has nanomolar affinity for the sigma 1 ( ⁇ -1) site, and has micromolar affinity for the sigma 2 ( ⁇ -2) site.
  • Haloperidol has similar affinities for both subtypes.
  • the Sigma-1 receptor is a non-opiaceous type receptor expressed in numerous adult mammal tissues (e.g. central nervous system, ovary, testicle, placenta, adrenal gland, spleen, liver, kidney, gastrointestinal tract) as well as in embryo development from its earliest stages, and is apparently involved in a large number of physiological functions. Its high affinity for various pharmaceuticals has been described, such as for SKF-10047, (+)- pentazocine, haloperidol and rimcazole, among others, known ligands with analgesic, anxiolytic, antidepressive, antiamnesic, antipsychotic and neuroprotective activity.
  • the sigma-1 receptor is of great interest in pharmacology in view of its possible physiological role in processes related to analgesia, anxiety, addiction, amnesia, depression, schizophrenia, stress, neuroprotection, psychosis and mood disorders (Kaiser et al (1991 ) Neurotransmissions 7 (1): 1-5; Walker, J.M. et al, Pharmacological Reviews, 1990, 42, 355; Bowen W.D. (2000) Pharmaceutica Acta Helvetiae 74: 211-218; and Hayashi, T. et al, Drugs of the Future 2009, 34 (2), 137).
  • the Sigma-2 receptor is also expressed in numerous adult mammal tissues (e.g. nervous system, immune system, endocrine system, liver, kidney).
  • Sigma-2 receptors can be components in a new apoptosis signaling pathway that may play an important role in regulating cell proliferation or in cell development. This pathway seems to consist of Sigma-2 receptors joined to intracellular membranes, located in organelles storing calcium, such as the endoplasmic reticulum and mitochondria, which also have the ability to release calcium from these organelles.
  • the calcium signals can be used in the signaling pathway for normal cells and/or in induction of apoptosis.
  • Agonists of Sigma-2 receptors induce changes in cell morphology, apoptosis in several types of cell lines and regulate the expression of p-glycoprotein mRNA, so that they are potentially useful as antineoplastic agents for the treatment of cancer.
  • Sigma-2 receptor agonists have been observed to induce apoptosis in mammary tumor cell lines resistant to common antineoplastic agents that induce DNA damage.
  • agonists of Sigma-2 receptors enhance the cytotoxic effects of these antineoplastic agents at concentrations at which the agonist is not cytotoxic.
  • agonists of Sigma-2 receptors can be used as antineoplastic agents at doses inducing apoptosis or at sub-toxic doses in combination with other antineoplasic agents to revert the resistance to the drug, thereby allowing the use of lower doses of the antineoplastic agent and considerably reducing its adverse effects.
  • Antagonists of Sigma-2 receptors can prevent the irreversible motor side effects caused by typical neuroleptic agents.
  • antagonists of Sigma-2 receptors can be useful as agents for improving the weakening effects of delayed dyskinesia appearing in patients due to chronic treatment of psychosis with typical antipsychotic drugs, such as haloperidol.
  • Sigma-2 receptors also seem to play a role in certain degenerative disorders in which blocking these receptors could be useful.
  • Endogenous sigma ligands are not known, although progesterone has been suggested to be one of them.
  • Possible sigma-site-mediated drug effects include modulation of glutamate receptor function, neurotransmitter response, neuroprotection, behavior, and cognition (Quirion, R. et al. Trends Pharmacol. Sci., 1992, 13:85-86).
  • Most studies have implied that sigma binding sites (receptors) are plasmalemmal elements of the signal transduction cascade.
  • Drugs reported to be selective sigma ligands have been evaluated as antipsychotics (Hanner, M. et al. Proc. Natl. Acad. Sci., 1996, 93:8072-8077).
  • the existence of sigma receptors in the CNS, immune and endocrine systems have suggested a likelihood that it may serve as link between the three systems.
  • Spirofbenzopyran] or spirofbenzofuran] derivatives were also disclosed in EP1847542 as well as pyrazole derivatives (EP1634873) with pharmacological activity on sigma receptors.
  • WO2008055932 deals with 1 ,2,4-triazole compounds having good activity towards sigma receptors.
  • WO2008/055933 deals with 1 ,2,3-triazole compounds having good activity towards sigma receptors.
  • WO2009071657 also reports tricyclic triazolic compounds having good activity towards sigma receptors.
  • the present invention relates to new 1 ,2,3-triazole-amine derivatives, having affinity for sigma receptors, especially sigma-1 receptor, as well as to the process for the preparation thereof, to compositions comprising them, and to their use as medicaments for the treatment of sigma receptor related diseases and disorders.
  • One aspect of the present invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I):
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; or
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached an at least mono-cyclic, substituted or unsubstituted, at least one heteroatom containing heterocyclyl group which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system;
  • R4 is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group
  • R 5 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyi group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system;
  • R 6 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyi group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system;
  • Z is selected from S or O;
  • R 8 is a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical;
  • n is 1 , 2, 3, or 4; optionally as of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or as a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • prodrug is used in its broadest sense and encompasses those derivatives that are converted in vivo to the compounds of the invention. Such derivatives would readily occur to those skilled in the art, and include, depending on the functional groups present in the molecule and without limitation, the following derivatives of the present compounds: esters, amino acid esters, phosphate esters, metal salts sulfonate esters, carbamates, and amides. Examples of well known methods of producing a prodrug of a given acting compound are known to those skilled in the art and can be found e.g. in Krogsgaard-Larsen et al. "Textbook of Drug design and Discovery” Taylor and Francis (April 2002).
  • alkyl radical or group is understood as meaning saturated and unsaturated, linear or branched hydrocarbons, which can be unsubstituted or mono- or polysubstituted.
  • saturated alkyl encompasses e.g. -CH 3 and -CH 2 -CH 3 .
  • C 1-2 -alkyl represents C1 - or C2-alkyl
  • Ci -3 -alkyl represents C1-, C2- or C3-alkyl
  • C 1-4 -alkyl represents C1-, C2-, C3- or C4-alkyl
  • d -5 -alkyl represents C1- C2-, C3-, C4-, or C5-alkyl
  • C 1-6 -alkyl represents C1-, C2-, C3-, C4-, C5- or C6-alkyl
  • Ci -8 -alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7- or C8-alkyl
  • C 1-10 -alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9- or C10-alkyl
  • d.ia-alkyl represents C1-, C2-, C3-, C4-, C5-, C6-, C7-, C8-, C9-, C10-, C1 1-, C12-, C13-, C14-, C15-, C16-, C17- or C18-alkyl.
  • the alkyl radicals are preferably methyl, ethyl, vinyl (ethenyl), propyl, allyl (2-propenyl), 1-propinyl, methylethyl, butyl, 1- methylpropyl, 2-methylpropyl, 1 ,1-dimethylethyl, pentyl, 1 ,1-dimethylpropyl, 1 ,2- dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, if substituted also CHF 2 , CF 3 or CH 2 OH etc.
  • aliphatic group or radical includes alkyi (saturated), alkenyl (unsaturated alkyi) and alkynyl (unsaturated alkyi) and thus is synonymous for: saturated or unsaturated alkyi (see above).
  • alkoxy group is an alkyi (carbon and hydrogen chain) group singular bonded to oxygen (R— O).
  • Preferred alkoxy groups are methoxy (CH 3 0— ), ethoxy (C 2 H 5 O— ), propoxy (C 3 H 7 0— ), or butoxy (C 4 H 9 0— ).
  • cycloalkyl radical or group is understood as meaning saturated and unsaturated (but not aromatic) cyclic hydrocarbons (without a heteroatom in the ring), which can be unsubstituted or mono- or polysubstituted.
  • C 3- 4-cycloalkyl represents C3- or C4-cycloalkyl
  • C3-5-cycloalkyl represents C3-, C4- or C5-cycloalkyl
  • C 3-6 - cycloalkyl represents C3-, C4-, C5- or C6-cycloalkyl
  • Cs-7-cycloalkyl represents C3-, C4-, C5-, C6- or C7-cycloalkyl
  • C 3-8 -cycloalkyl represents C3-, C4-, C5-, C6-, C7- or C8-cycloalkyl
  • C 4-5 - cycloalkyl represents C4- or C5-cycloalkyl
  • C4-6-cycloalkyl represents C4-, C5- or C6- cycloalkyl
  • Cs-e-cycloalkyl represents C5- or C6
  • alkyi and cycloalkyl radicals are preferably methyl, ethyl, vinyl (ethenyl), propyl, allyl (2- propenyl), 1-propinyl, methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1 ,1-dimethylethyl, pentyl, 1 ,1-dimethylpropyl, 1 ,2-dimethylpropyl, 2,2-dimethylpropyl, hexyl, 1-methylpentyl, cyclopropyl, 2-methylcyclopropyl, cyclopropylmethyl, cyclobutyl, cyclopentyl, cyclopentylmethyl, cyclohexyl, cycloheptyl,
  • Particularly preferred cycloalkyls are cyclopropane, cyclohexyl, and adamantyl.
  • alkyl-cycloalkyl is understood as meaning a cycloalkyl group (see above) being connected to another atom through an alkyi group (see above), whereas the alkyi is always saturated and linear or branched always refers to the alkyi.
  • Preferred substituents are halogen, substituted or unsubstituted Ci -6 -alkyl, a saturated or unsaturated, linear or branched, substituted or unsubstituted -0-C 1-6 -alkyl (alkoxy).
  • Very preferred substituents are fluoro, chloro, methyl, ethanone.
  • (CH 2 )3- 6 is to be understood as meaning -CH 2 -CH 2 -CH 2 -, -CH 2 -CH 2 -CH 2 -, - CH 2 -CH 2 -CH 2 -CH 2 - and -CH 2 -CH 2 -CH 2 -CH 2 -CH 2 -, (CH 2 ) 1-4 is to be understood as meaning -CH 2 - -CH 2 -CH 2 -, -CH2-CH2-CH2- and -CH2-CH2-CH2-CH2-, (CH 2 )4-5 is to be understood as meaning -CH 2 -CH 2 -CH 2 -CH 2 - and -CHz-CHz-CHz-CHz- etc.
  • aryl radical or group is understood as meaning ring systems with at least one aromatic ring but without heteroatoms even in only one of the rings. Examples are phenyl, naphthyl, fluoranthenyl, fluorenyl, tetralinyl or indanyl, radicals, which can be unsubstituted or monosubstituted or polysubstituted.
  • aryls are phenyl and naphthyl.
  • alkyl-aryl is understood as meaning an aryl group (see above) being connected to another atom through an alkyl-group (see above), whereas the alkyl is always saturated and linear or branched always refers to the alkyl.
  • a peferred alkyl-aryl group is benzyl.
  • a heterocyclyl radical or group is understood as meaning heterocyclic ring systems, saturated or unsaturated ring which contains one or more heteroatoms from the group consisting of nitrogen, oxygen and/or sulfur in the ring and can also be mono- or polysubstituted.
  • heteroaryls examples which may be mentioned from the group of heteroaryls are furan, benzofuran, thiophene, benzothiophene, pyrrole, pyridine, pyrimidine, pyrazine, quinoline, isoquinoline, phthalazine, benzo-1 ,2,5-thiadiazole, benzothiazole, indole, benzotriazole, benzodioxolane, benzodioxane, carbazole.quinazoline, further heterocycles according to the invention are pyran, pyrrolidine, piperazine, piperidine, imidazole, thiazole, morpholine, azepane; and oxazepane.
  • heterocyclyl radicals are pyrrolidine, piperazine, piperidine, morpholine, azepane; and oxazepane.
  • alkyl-heterocylyl is understood as meaning a heterocyclyl group (see above) being connected to another atom through an alkyl group (see above), whereas the alkyl is always saturated and linear or branched always refers to the alkyl.
  • Preferred substituents are halogen, substituted or unsubstituted Ci -6 -alkyl, a saturated or unsaturated, linear or branched, substituted or unsubstituted -0-Ci -6 -alkyl (alkoxy).
  • Very preferred substituents are fluoro, chloro, methyl, ethanone.
  • ring system refers to ring sytems comprising saturated or unsaturated or aromatic carbocyclic ring sytems which contain optionally at least one heteroatom selected from N, O or S as ring member and which are substituted or unsubstituted. Said ring systems may be condensed to other carbocyclic ring systems such as aryl groups, heterocyclyl groups, cycloalkyl groups, etc.
  • condensed means that a ring or ring-system is attached to another ring or ring-system, whereby the terms “annulated” or “annelated” are also used by those skilled in the art to designate this kind of attachment.
  • salt is to be understood as meaning any form of the active compound used according to the invention in which it assumes an ionic form or is charged and is coupled with a counter-ion (a cation or anion) or is in solution.
  • a counter-ion a cation or anion
  • complexes of the active compound with other molecules and ions in particular complexes which are complexed via ionic interactions.
  • physiologically acceptable salt means in the context of this invention any salt that is physiologically tolerated (most of the time meaning not being toxic-especially not caused by the counter-ion) if used appropriately for a treatment especially if used on or applied to humans and/or mammals.
  • physiologically acceptable salts can be formed with cations or bases and in the context of this invention it is understood as meaning salts of at least one of the compounds used according to the invention - usually a (deprotonated) acid - as an anion with at least one, preferably inorganic, cation which is physiologically tolerated - especially if used on humans and/or mammals.
  • the salts of the alkali metals and alkaline earth metals are particularly preferred, and also those with NH 4 , but in particular (mono)- or (di)sodium, (mono)- or (di)potassium, magnesium or calcium salts.
  • physiologically acceptable salts can also be formed with anions or acids in the context of this invention is understood as meaning salts of at least one of the compounds used according to the invention - usually protonated, for example on the nitrogen - as the cation with at least one anion which are physiologically tolerated - especially if used on humans and/or mammals.
  • the salt formed with a physiologically tolerated acid that is to say salts of the particular active compound with inorganic or organic acids which are physiologically tolerated - especially if used on humans and/or mammals.
  • physiologically tolerated salts of particular acids are salts of: • hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, malic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid or citric acid.
  • the compounds of the invention may be in crystalline form or either as free compounds or as solvates and it is intended that those forms are within the scope of the present invention.
  • Methods of solvation are generally known within the art. Suitable solvates are pharmaceutically acceptable solvates.
  • the term "solvate" according to this invention is to be understood as meaning any form of the active compound according to the invention in which this compound has attached to it via non-covalent binding another molecule (most likely a polar solvent) especially including hydrates and alcoholates, e.g. methanolate.
  • prodrug is used in its broadest sense and encompasses those derivatives that are converted in vivo to the compounds of the invention. Such derivatives would readily occur to those skilled in the art, and include, depending on the functional groups present in the molecule and without limitation, the following derivatives of the present compounds: esters, amino acid esters, phosphate esters, metal salts sulfonate esters, carbamates, and amides. Examples of well known methods of producing a prodrug of a given acting compound are known to those skilled in the art and can be found e.g. in Krogsgaard-Larsen et al. "Textbook of Drug design and Discovery” Taylor and Francis (April 2002).
  • the compounds of the invention are also meant to include compounds which differ only in the presence of one or more isotopicaliy enriched atoms.
  • compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 1 C-enriched carbon or 15 N-enriched nitrogen are within the scope of this invention.
  • the compounds of formula (I) or their salts or solvates are preferably in pharmaceutically acceptable or substantially pure form.
  • pharmaceutically acceptable form is meant, inter alia, having a pharmaceutically acceptable level of purity excluding normal pharmaceutical additives such as diluents and carriers, and including no material considered toxic at normal dosage levels.
  • Purity levels for the drug substance are preferably above 50 percent, more preferably above 70 percent, most preferably above 90 percent. In a preferred embodiment it is above 95 percent of the compound of formula (I) or, or of its salts, solvates or prodrugs.
  • the term "pharmacological tool” refers to the property of compounds of the invention through which they are particularly selective ligands for Sigma receptors which implies that compound of formula (I), described in this invention, can be used as a model for testing other compounds as sigma ligands, ex. a radiactive ligands being replaced, and can also be used for modeling physiological actions related to sigma receptors.
  • Another preferred embodiment of the invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I), wherein
  • R 5 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted alkyl radical; an substituted or unsubstituted, C 3 -C 6 cycloalkyl group; an substituted or unsubstituted, at least six-membered aryl group;
  • R 6 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted C 1-4 alkyl radical; an substituted or unsubstituted, at least six- membered aryl group;
  • Z is selected from S or O; wherein R 8 is a linear or branched, saturated or unsaturated, substituted or unsubstituted Ci -4 alkyl radical.
  • R 6 is selected from the group consisting of a substituted or unsubstituted methyl group; a substituted or unsubstituted phenyl group; wherein the substituents are selected from halogen;
  • Z is selected from S or O
  • Rs is a linear or branched, saturated or unsaturated, substituted or unsubstituted alkyl radical.
  • Another preferred embodiment of the invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I), wherein Ri and R 2 , identical or different, are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted C 1-4 alkyl radical; or
  • Rt and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with an substituted or unsubstituted mono- or polycyclic ring system, wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted, wherein the substituents are selected from the group consisting of C1-C4 alkyl, (- -C4 alkoxy, halogen, C 3 -C 6 cycloalkyl; preferably
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, substituted or unsubstituted ethyl group; or
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a substituted or unsubstituted heterocyclyl group, selected from the group consisting of a pyrrolidine group, a piperazine group, a piperidine group, a morpholine group, an azepane group or an oxazepane group, the heterocyclyl group being unsubstituted or substituted, wherein the substituents are selected from the group consisting of a methyl group, an ethanone group, a fluoro group, a chloro group or a cyclohexyl group.
  • R4 is selected from the group consisting of an substituted or unsubstituted C 6 -Ci 0 cycloalkyl group, which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted at least six membered aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyl group is at least six membered and may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system; a branched or unbranched, saturated, substituted or unsubstituted alkyl-
  • R 4 is selected from the group consisting of a substituted or unsubstituted cyclohexyl group; an substituted or unsubstituted adamantyl group; a substituted or unsubstituted phenyl group; a substituted or unsubstituted benzyl group; a substituted or unsubstituted naphtalene group; wherein the substituents are selected from fluoro and chloro.
  • Another very preferred embodiment of the invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I), wherein n is 1 or 2.
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted alkyl radical; or
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system; wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted; wherein the substituents are selected from the group consisting of C 1 -C4 alkyl, C C 4 alkoxy, halogen, C 3 -C 6 cycloalkyl;
  • R 4 is selected from the group consisting of an substituted or unsubstituted C 6 -Ci 0 cycloalkyl group, which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted at least six membered aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyl group is at least six membered and may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group is at least six membered and/or condensed with a mono- or poly
  • R 5 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted Ci-4 alkyl radical; an substituted or unsubstituted, C 3 -C 6 cycloalkyl group; an substituted or unsubstituted, at least six-membered aryl group;
  • R 6 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted C 1-4 alkyl radical; an substituted or unsubstituted, at least six- membered aryl group;
  • Z is selected from S or O; wherein R 8 is a linear or branched, saturated or unsaturated, substituted or unsubstituted Ci -4 alkyl radical.
  • Ri and R 2 are a substituted or unsubstituted ethyl group; or i and R 2 form together with the bridging nitrogen atom to which they are attached a heterocyclyl group selected from the group consisting of a pyrrolidine group, a piperazine group, a piperidine group, a morpholine group, an azepane group, an oxazepane group; the heterocyclyl group being unsubstituted or substituted; wherein the substituents are selected from the group consisting of a methyl group, an ethanone group, a fluoro, a chloro or a cyclohexyl group;
  • R is selected from the group consisting of a substituted or unsubstituted cyclohexyl group, an substituted or unsubstituted adamantyl group, a substituted or unsubstituted phenyl group, a substituted or unsubstituted benzyl group, a substituted or unsubstituted naphtalene group; wherein the substituents are selected from fluoro and chloro;
  • R 5 is selected from the group consisting of a methyl group; a tert-butyl group; a cyclopropane group; a cyclohexyl group; a phenyl group;
  • R 6 is selected from the group consisting of a methyl group; a substituted phenyl group; wherein the substituent is chloro,
  • R 8 is propyl: n is 1 or 2.
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a heterocyclyl group selected from the group consisting of a pyrrolidin group, a piperazine group, a piperidine group, a morpholine group, an azepane group; an oxazepane group; the heterocyclyl group being unsubstituted or substituted; wherein the substituents are selected from the group consisting of a methyl group, an ethanone group, a fluoro group, a chloro group or a cyclohexyl group;
  • R 4 is selected from the group consisting of a cyclohexyl group, an adamantyl group; a substituted or unsubstituted phenyl group; a substituted or unsubstituted benzyl group; a naphtalene group; wherein the substituents are selected from fluor and chloro;
  • R 5 is selected from the group consisting of a methyl group; a tert-butyl group; a cyclopropane group; a cyclohexyl group; an phenyl group;
  • R 6 is selected from the group consisting of a methyl group; a substituted phenyl group; wherein the substituent is chloro;
  • R 8 is propyl; n is 1 or 2.
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; or
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached an at least mono-cyclic, substituted or unsubstituted, at least one heteroatom containing heterocyclyl group which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system;
  • R4 is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group in which the cycloalkyi group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group may be substituted or un
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted C -4 alkyl radical; or
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with an substituted or unsubstituted mono- or polycyclic ring system; wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted, wherein the substituents are selected from the group consisting of C 1 -C4 alkyl, Ci-C 4 alkoxy, halogen, C 3 -C 6 cycloalkyl; preferably
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, substituted or unsubstituted ethyl group; or
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a substituted or unsubstituted heterocyclyl group, selected from the group consisting of a pyrrolidine group, a piperazine group, a piperidine group, a morpholine group, an azepane group or an oxazepane group; the heterocyclyl group being unsubstituted or substituted, wherein the substituents are selected from the group consisting of a methyl group, an ethanone group, a fluoro group, a chloro group or a cyclohexyl group.
  • Another preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has a structure of general formula (la):
  • R4 is selected from the group consisting of an substituted or unsubstituted C 6 -Ci 0 cycloalkyi group, which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted at least six membered aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyi group is at least six membered and may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group is at least six membered and/or condensed with a mono- or poly
  • R4 is selected from the group consisting of a substituted or unsubstituted cyclohexyl group; an substituted or unsubstituted adamantyl group; a substituted or unsubstituted phenyl group; a substituted or unsubstituted benzyl group; a substituted or unsubstituted naphtalene group; wherein the substituents are selected from fluoro and chloro.
  • n 1 or 2.
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted Ci -4 alkyl radical; or
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system; wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted; wherein the substituents are selected from the group consisting of C C 4 alkyl, C 1 -C4 alkoxy, halogen, C 3 -C 6 cycloalkyi;
  • R4 is selected from the group consisting of an substituted or unsubstituted C 6 -C 10 cycloalkyi group, which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted, at least six membered aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyi group is at least six membered and may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group is at least six membered and/or condensed with a mono- or polycycl
  • Ri and R 2 are an ethyl group
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a heterocyclyl group selected from the group consisting of a pyrrolidin group, a piperazine group, a piperidine group, a morpholine group, an azepane group, an oxazepane group; the heterocyclyl group being unsubstituted or substituted; wherein the substituents are selected from the group consisting of a methyl group, an ethanone group, a fluoro, a chloro or a cyclohexyl group;
  • R4 is selected from the group consisting of a cyclohexyl group; an adamantyl group; a substituted or unsubstituted phenyl group, a substituted or unsubstituted benzyl group, a naphtalene group; wherein the substituents are selected from fluoro and chloro, n is 1 or 2.
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; or
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached an at least mono-cyclic, substituted or unsubstituted, at least one heteroatom containing heterocyclyl group which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system;
  • R4 is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycloalkyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group in
  • R 5 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycloalkyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyl group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system;
  • a preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has a structure of general formula (lb):
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached an at least mono-cyclic, substituted or unsubstituted, at least one heteroatom containing heterocyclyl group which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system;
  • R4 is selected from the group consisting of a a substituted or unsubstituted cycloalkyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system;
  • R 5 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycloalkyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; n is 1 , 2, 3, or 4; optionally as one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or as of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • Another preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives
  • R 5 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted C 1-4 alkyl radical; an substituted or unsubstituted, C 3 -C 6 cycloalkyl group; an substituted or unsubstituted, at least six-membered aryl group.
  • Item 1 1 Another preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has a structure of general formula (lb):
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with an substituted or unsubstituted mono- or polycyclic ring system; wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted, wherein the substituents are selected from the group consisting of C1-C4 alkyl, C1-C4 alkoxy, halogen, C 3 -C 6 cycloalkyl; preferably
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a substituted or unsubstituted heterocyclyl group, selected from the group consisting of a pyrrolidine group, a piperazine group, a piperidine group, a morpholine group, an azepane group or an oxazepane group; the heterocyclyl group being unsubstituted or substituted, wherein the substituents are selected from the group consisting of a fluoro group, a chloro group.
  • a substituted or unsubstituted heterocyclyl group selected from the group consisting of a pyrrolidine group, a piperazine group, a piperidine group, a morpholine group, an azepane group or an oxazepane group
  • the heterocyclyl group being unsubstituted or substituted, wherein the substituents are selected from the group consisting of a fluoro group, a chloro group.
  • R4 is selected from the group consisting of an substituted or unsubstituted C 6 -C 10 cycloalkyl group, which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted at least six membered aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group is at least six membered and/or condensed with a mono- or polycyclic ring system; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted; wherein the substituents are selected from halogen.
  • Another preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has
  • R4 is selected from the group consisting of a substituted or unsubstituted adamantyl group; a substituted or unsubstituted phenyl group; a substituted or unsubstituted benzyl group; wherein the substituents are selected from fluoro and chloro.
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system; wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted; wherein the substituents are selected from the group consisting of Ci-C 4 alkyl, C ⁇ C 4 alkoxy, halogen, C 3 -C 6 cycloalkyl;
  • R4 is selected from the group consisting of an substituted or unsubstituted C 6 -C 10 cycloalkyl group, which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted at least six membered aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group is at least six membered and/or condensed with a mono- or polycyclic ring system; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted; wherein the substituents are selected from halogen;
  • R 5 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted Ci -4 alkyl radical; an substituted or unsubstituted, C 3 -C 6 cycloalkyl group; an substituted or unsubstituted, at least six-membered aryl group.
  • Another preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has a structure of general formula (I), wherein the compound has a structure of general formula
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a a morpholine group
  • R4 is selected from the group consisting of an adamantyl group; a substituted phenyl group, a substituted benzyl group, a naphtalene group; wherein the substituents are selected from chloro;
  • R 5 is selected from the group consisting of a methyl group; a tert-butyl group; a cyclopropane group; a cyclohexyl group; a phenyl group; n is 1.
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; or
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached an at least mono-cyclic, substituted or unsubstituted, at least one heteroatom containing heterocyclyl group which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system;
  • R 4 is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycioalkyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group in which the cycioalkyl group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group
  • R 6 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycioalkyl group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system; n is 1 , 2, 3, or 4; optionally as one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or as of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached an at least mono-cyclic, substituted or unsubstituted, at least one heteroatom containing heterocyclyl group which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system;
  • R4 is selected from the group consisting of a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems;
  • R 6 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; n is 1 , 2, 3, or 4; optionally as one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or as of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • a preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has a structure of general formula (lc):
  • R 6 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted C 1-4 alkyl radical; an substituted or unsubstituted, at least six- membered aryl group; preferably
  • R 6 is selected from the group consisting of a substituted or unsubstituted methyl group; a substituted or unsubstituted phenyl group; wherein the substituents are selected from halogen.
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with an substituted or unsubstituted mono- or polycyclic ring system; wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted, wherein the substituents are selected from the group consisting of C C 4 alkyl, C 1 -C4 alkoxy, halogen, C 3 -C 6 cycloalkyl; preferably
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a substituted or unsubstituted heterocyclyl group, selected from the group consisting of a pyrrolidine group, a piperazine group, a piperidine group, a morpholine group, an azepane group or an oxazepane group; the heterocyclyl group being unsubstituted or substituted, wherein the substituents are selected from the group consisting of a fluoro group or a chloro group.
  • a substituted or unsubstituted heterocyclyl group selected from the group consisting of a pyrrolidine group, a piperazine group, a piperidine group, a morpholine group, an azepane group or an oxazepane group
  • the heterocyclyl group being unsubstituted or substituted, wherein the substituents are selected from the group consisting of a fluoro group or a chloro group.
  • R4 is selected from the group consisting of a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; wherein the substituents are selected from halogen.
  • R4 is selected from the group consisting of a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; wherein the substituents are selected from halogen.
  • R4 is a substituted or unsubstituted phenyl group; wherein the substituents are chloro.
  • n 1 or 2.
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system; wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted; wherein the substituents are selected from the group consisting of Ci-C 4 alkyl, C ⁇ C 4 alkoxy, halogen, C 3 -C 6 cycloalkyl;
  • R is a substituted or unsubstituted, at least six membered aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; wherein the substituents are selected from halogen;
  • R 6 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted d -4 alkyl radical; an substituted or unsubstituted, at least six- membered aryl group.
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a morpholine group
  • R4 is a substituted phenyl group, wherein the substituents are chloro;
  • R 6 is selected from the group consisting of a methyl group; a substituted phenyl group; wherein the substituents are chloro; n is 1.
  • R 7 is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems;
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; or
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached an at least mono-cyclic, substituted or unsubstituted, at least one heteroatom containing heterocyclyl group which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system;
  • R4 is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group in which the cycloalkyi group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group may be substituted or un
  • a preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has a structure of general formula (Id):
  • R 7 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted alkyl radical; an substituted or unsubstituted, at least six membered aryl group; preferably
  • R 7 is selected from the group consisting of a substituted or unsubstituted ethyl group; a substituted or unsubstituted propyl group; a substituted or unsubstituted benzyl group.
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with an substituted or unsubstituted mono- or polycyclic ring system; wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted, wherein the substituents are selected from the group consisting of C 1 -C4 alkyl, C 1 -C4 alkoxy, halogen, C 3 -C 6 cycloalkyl; preferably
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a substituted or unsubstituted heterocyclyl group, selected from the group consisting of a pyrrolidine group, a piperazine group, a piperidine group, a morpholine group, an azepane group or an oxazepane group; the heterocyclyl group being unsubstituted or substituted, wherein the substituents are selected from the group consisting of a fluoro group or a chloro group.
  • a substituted or unsubstituted heterocyclyl group selected from the group consisting of a pyrrolidine group, a piperazine group, a piperidine group, a morpholine group, an azepane group or an oxazepane group
  • the heterocyclyl group being unsubstituted or substituted, wherein the substituents are selected from the group consisting of a fluoro group or a chloro group.
  • R is selected from the group consisting of an substituted or unsubstituted C 6 -Ci 0 cycloalkyl group, which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted at least six membered aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group is at least six membered and/or condensed with a mono- or polycyclic ring system; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted; wherein the substituents are selected from halogen.
  • R4 is selected from the group consisting of a substituted or unsubstituted cyclohexyl group; an substituted or unsubstituted adamantyl group; a substituted or unsubstituted phenyl group; a substituted or unsubstituted benzyl group; a substituted or unsubstituted naphtaiene group; wherein the substituents are selected from fluoro and chloro.
  • n 1 or 2.
  • R 7 is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted Ci -4 alkyl radical; an substituted or unsubstituted, at least six membered aryl group;
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with a substituted or unsubstituted mono- or poiycyciic ring system; wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or poiycyciic ring system being unsubstituted or substituted; wherein the substituents are selected from the group consisting of C 1 -C4 alkyl, C 1 -C 4 alkoxy, halogen, C 3 -C 6 cycloalkyl;
  • R4 is selected from the group consisting of an substituted or unsubstituted C 6 -Ci 0 cycloalkyl group, which is optionally condensed to other, substituted or unsubstituted, mono- or poiycyciic ring systems; an substituted or unsubstituted at least six membered aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or poiycyciic ring systems; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group is at least six membered and/or condensed with a mono- or poiycyciic ring system; the heterocyclyl group and/or mono- or poiycyciic ring system being unsubstituted or substituted; wherein the substituents are selected from halogen.
  • Another preferred embodiment of the invention relates to 1 ,
  • R 7 is selected from the group consisting of an ethyl group; a propyl group; a substituted benzyl group; wherein the substituents are selected from chloro;
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a heterocyclyl group selected from the group consisting of a piperidine group, a morpholine group;
  • R4 is selected from the group consisting of an adamantyl group; a substituted phenyl group, a substituted or unsubstituted benzyl group, wherein the substituents are selected from chloro; n is 1 or 2.
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; or
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached an at least mono-cyclic, substituted or unsubstituted, at least one heteroatom containing heterocyclyl group which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system;
  • R4 is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group in which the cycloalkyi group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system; a branched or unbranched, saturated, substituted or unsubstituted alkyl-aryl group in which the aryl group may be substituted or un
  • Z is selected from S or O
  • R 8 is a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; n is 1 , 2, 3, or 4; optionally as one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or as of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • a preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has a structure of general formula (le):
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached an at least mono-cyclic, substituted or unsubstituted, at least one heteroatom containing heterocyclyl group which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system;
  • * is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems;
  • Z is selected from S or O
  • R 8 is a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; n is 1 , 2, 3, or 4; optionally as one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or as of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof.
  • Another preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has a structure of general formula (le):
  • Z is selected from S or O
  • R 8 is a linear or branched, saturated or unsaturated, substituted or unsubstituted d -4 alkyl radical; more preferably
  • Z is selected from S or O
  • R 8 is a linear or branched, saturated or unsaturated, substituted or unsubstituted Ci -4 alkyl radical.
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with an substituted or unsubstituted mono- or polycyclic ring system; wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted, wherein the substituents are selected from the group consisting of C 1 -C4 alkyl, C 1 -C4 alkoxy, halogen, C 3 -C 6 cycloalkyl; preferably
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a substituted or unsubstituted heterocyclyl group, selected from the group consisting of a pyrrolidine group, a piperazine group, a piperidine group, a morpholine group, an azepane group or an oxazepane group; the heterocyclyl group being unsubstituted or substituted, wherein the substituents are selected from the group consisting of a methyl group, an ethanone group, a fluoro group, a chloro group or a cyclohexyl group.
  • Another preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has a structure of general formula (le):
  • R4 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems.
  • Another preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has a structure of general formula (le):
  • R is selected from the group consisting of a substituted or unsubstituted aryl group; wherein the substituents are selected from halogen.
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a monocyclic, substituted or unsubstituted, at least one heteroatom containing C 5 -C 7 heterocyclyl group, which is optionally condensed with a substituted or unsubstituted mono- or polycyclic ring system; wherein the heteroatom is selected from the group consisting of N, S, O; the heterocyclyl group and/or mono- or polycyclic ring system being unsubstituted or substituted; wherein the substituents are selected from the group consisting of Ci-C 4 alkyl, C4 alkoxy, halogen, C 3 -C 6 cycloalkyl;
  • R4 is selected from the group consisting of an substituted or unsubstituted, at least six membered aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; wherein the substituents are selected from halogen;
  • Z is selected from S or O
  • R 8 is a linear or branched, saturated or unsaturated, substituted or unsubstituted d -4 alkyl radical.
  • Item 42 Another preferred embodiment of the invention relates to 1 ,2,3,-triazole-4-amine derivatives of general formula (I), wherein the compound has a structure of general formula (le): according to any of items 34) through 41 ), wherein
  • Ri and R 2 form together with the bridging nitrogen atom to which they are attached a morpholine group
  • R4 is a substituted phenyl group; wherein the substituents are chloro;
  • R 8 is propyl; n is 1 .
  • the most preferred embodiment of the invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I), wherein the derivative is selected from the group consisting of
  • Another aspect of the present invention relates to a process for the production of a 1 ,2,3- triazole-4-amine derivatives of general formula (I).
  • the 1 ,2,3-triazole-4-amine derivatives of general formula (I) can be obtained by the following methods:
  • PGi-Deprotection of a compound of formula (IX) is generally carried out by conventional procedures known by those skilled in the art (e.g. Greene, T. W., Wutz P. M. "Protective Groups in Organic Synthesis” Wiley, 1999).
  • the PG 2 -deprotection of compounds of formula (VII) is typically carried out in an aprotic solvent such as THF with an appropriate reagent such as TBAF.
  • the subsequent cycloaddtion reaction is preferably carried out in situ by the addition of an organic azide (VIII), catalytic amounts of a Cu(l) salt such as Cul, and an excess of a base, preferably a tertiary amine such as DIPEA, at ambient temperature to give 1 ,4-disubstituted 1 ,2,3- triazoles of formula (IX) (adapted from B. K. Sharpless et al., Angew. Chem. Int. Ed. 2002, 41 , 2596-2599).
  • the organic azides of formula (VIII) are commercially available or can be prepared by conventional procedures.
  • X can be Br, CI....
  • the /V-Alkylation of compounds of formula (V) is preferably carried out in an aprotic solvent such as dichloromethane in the presence of an organic base such as DIPEA with an alkylating agent (IV).
  • Acylation of compounds of formula (la) is preferably carried out in an aprotic solvent such as dichloromethane in the presence of an organic base such as DIPEA with an acyl chloride of formula (X) or, alternatively, in neat acetic anhydride.
  • an aprotic solvent such as dichloromethane
  • an organic base such as DIPEA
  • an acyl chloride of formula (X) or, alternatively, in neat acetic anhydride.
  • R 7 is as defined herein; and which comprises the reaction of compound of formula (la) with an aldehyde (XII).
  • XII aldehyde
  • Reductive amination is typically carried out in the presence of a reducing agent such as NaBH(OAc) 3 or NaBH 3 CN in a solvent such as methanol or dichloroethane at reflux temperature or under heated microwave conditions.
  • a reducing agent such as NaBH(OAc) 3 or NaBH 3 CN
  • a solvent such as methanol or dichloroethane
  • reaction of compounds of formula (la) and compounds of formula (XIII) is preferably carried out in an aprotic solvent such as dichloromethane in the presence of an organic base such as TEA or DIPEA preferably at reflux temperature.
  • an aprotic solvent such as dichloromethane
  • an organic base such as TEA or DIPEA preferably at reflux temperature.
  • Another aspect of the present invention relates to a process for the production of 1 ,2,3- triazole-4-amine derivatives of general formula (I)
  • the PG 2 -deprotection of compounds of formula (VII) can optionally be carried out in an aprotic solvent, such as THF, with an appropriate reagent, such as TBAF, and wherein the subsequent cycloaddtion reaction is optionallly carried out in situ by the addition of catalytic amounts of a Cu(l) salt, and an excess of a base, preferably a tertiary amine such as DIPEA, wherein the compounds of formula (VII) can be prepared from compounds of formula (III):
  • reaction comprises copper catalyzed alkynylation.
  • the compounds of general formula (I) themselves are obtained as a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or fractionalized crystallization with chiral reagents. If there are chiral centers the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution.
  • Solvates preferably hydrates, of the compounds of general formula (I), of corresponding stereoisomers, or of corresponding salts thereof may also be obtained by standard procedures known to those skilled in the art.
  • inventive compounds of general formula (I), of a corresponding stereoisomer, or salt, or solvate or any intermediate thereof may, if required, be carried out by conventional methods known to those skilled in the art, e.g. chromatographic methods or recrystallization.
  • the compounds of general formula (I) themselves are obtained as a mixture of stereoisomers, particularly enantiomers or diastereomers, said mixtures may be separated by standard procedures known to those skilled in the art, e.g. chromatographic methods or fractionalized crystallization with chiral reagents. If there are chiral centers, the compounds may be prepared in racemic form, or individual enantiomers may be prepared either by enantiospecific synthesis or by resolution. Solvates, preferably hydrates, of the compounds of general formula (I), of corresponding stereoisomers, or of corresponding salts thereof may also be obtained by standard procedures known to those skilled in the art.
  • Gi is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; an substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or poiycyclic ring systems; an substituted or unsubstituted carbonyl group; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or poiycyclic ring systems; an substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or poiycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group in which the cycloalkyi group may be substituted or unsub
  • R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; an substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or poiycyclic ring systems; an substituted or unsubstituted carbonyl group; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or poiycyclic ring systems; an substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or poiycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyi group may
  • R4 is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; an substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted carbonyl group; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group in which the cycloalkyi group may be substituted or unsubstituted and
  • R 5 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyi group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system;
  • Z is selected from S or O
  • R 8 is a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; n is 1 , 2, 3, or 4; optionally as one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or as a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate or prodrug thereof; for use as a medicament.
  • Another aspect of the invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I):
  • Gi is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; an substituted or unsubstituted cycloalkyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted carbonyl group; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group in which the cycloalkyi group may be substituted or unsubstituted and/
  • Ri and R 2 are selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; an substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted carbonyl group; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyi group may be substituted or un
  • R4 is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; an substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted carbonyl group; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group in which the cycloalkyi group may be substituted or unsubstituted and
  • R5 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycloalkyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyl group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system;
  • Z is selected from S or O
  • R 8 is a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; n is 1 , 2, 3, or 4; optionally as of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or as a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate or a prodrug thereof; for use in the treatment or prophylaxis of sigma receptor mediated diseases or conditions.
  • Another preferred embodiment of the invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I):
  • Gi is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; an substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted carbonyl group; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group in which the cycloalkyi group may be substituted or unsubstituted and/
  • R4 is selected from the group consisting of a hydrogen atom; a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; an substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted carbonyl group; an substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; an substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl- cycloalkyl group in which the cycloalkyi group may be substituted or unsubstituted and
  • R 5 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted cycloalkyi group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a substituted or unsubstituted heterocyclyl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyl group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system;
  • R 6 is selected from the group consisting of a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; a substituted or unsubstituted aryl group which is optionally condensed to other, substituted or unsubstituted, mono- or polycyclic ring systems; a branched or unbranched, saturated or unsaturated, substituted or unsubstituted alkyl-cycloalkyl group in which the cycloalkyl group may be substituted or unsubstituted and/or condensed with a mono- or polycyclic ring system;
  • Z is selected from S or O
  • R 3 is a linear or branched, saturated or unsaturated, substituted or unsubstituted aliphatic radical; n is 1 , 2, 3, or 4; optionally as one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in as a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate or a prodrug thereof; for use in the preparation of a medicament for the modulation of sigma receptors, preferably for the treatment or prophylaxis of sigma receptor mediated diseases or conditions.
  • the disease and/or condition is selected from diarrhea, lipoprotein disorders, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, migraine, arthritis, hypertension, arrhythmia, ulcer, glaucoma, learning, memory and attention deficits, cognition disorders, neurodegenerative diseases, demyelinating diseases, addiction to drugs and chemical substances including ***e, amphetamine, ethanol and nicotine; tardive diskinesia, ischemic stroke, epilepsy, stroke, stress, cancer, psychotic conditions, in particular depression, anxiety or schizophrenia; inflammation or autoimmune diseases, for the treatment and prophylaxis of pain, especially neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia.
  • the disease and/or condition is selected from the group consisting of pain, preferably neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia.
  • the disease and/or condition is allodynia and/or hyperalgesia.
  • the disease and/or condition is mechanical or thermal allodynia, preferably mechanical allodynia.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising one or more compounds of general formula (I), or isomers, solvates or prodrugs thereof, and at least one pharmaceutically acceptable excipient.
  • One preferred pharmaceutically acceptable form of the compounds of the invention is the crystalline form, including such form in pharmaceutical composition.
  • the additional ionic and solvent moieties must also be non-toxic.
  • the compounds of the invention may present different polymorphic forms, it is intended that the invention encompasses all such forms.
  • Another aspect of the present invention relates to a medicament comprising at least one compound of general formula (I) given above, said compound being optionally in form of one of the stereoisomers, preferably enantiomers or diastereomers, a racemate or in form of a mixture of at least two of the stereoisomers, preferably enantiomers and/or diastereomers, in any mixing ratio, or a corresponding salt thereof, or a corresponding solvate thereof; or a prodrug thereof.
  • Another aspect of the invention is a medicament comprising at least one combination of compounds according to the invention and optionally one or more pharmaceutically acceptable excipients.
  • Said medicament may also comprise any combination of one or more of the compounds of general formula (I) given above, stereoisomers thereof, physiologically acceptable salts thereof or physiologically acceptable solvates or prodrugs thereof.
  • the compounds of the invention that is, the 1 ,2,3-triazole-4-amine derivatives of general formula (I) are contemplated for medical uses as described herein, be it in the form of a pharmaceutical composition as described herein, a medicament as described herein or any other pharmaceutically acceptable administration form suitable for administration to a patient.
  • the term "patient” refers to a mammal, preferably a human.
  • Another aspect of the invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I) for the use(s) and/or medical use(s) described herein, the 1 ,2,3-triazole-4-amine derivatives of general formula (I) optionally being in the form of said pharmaceutical composition, said medicament, or said pharmaceutical administration form, wherein the disease or condition is a sigma-1 mediated disease or condition.
  • Another aspect of the invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I) for the medical use(s) described herein, the 1 ,2,3-triazole-4-amine derivatives of general formula (I) optionally being in the form of said pharmaceutical composition, said medicament, or said pharmaceutical administration form, wherein the disease and/or condition is selected from diarrhea, lipoprotein disorders, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, migraine, arthritis, hypertension, arrhythmia, ulcer, glaucoma, learning, memory and attention deficits, cognition disorders, neurodegenerative diseases, demyelinating diseases, addiction to drugs and chemical substances including ***e, amphetamine, ethanol and nicotine; tardive diskinesia, ischemic stroke, epilepsy, stroke, stress, cancer, psychotic conditions, in particular depression, anxiety or schizophrenia; inflammation or autoimmune diseases, for the treatment and prophylaxis of pain, especially neuropathic pain, inflammatory pain or other pain conditions involving allodynia
  • a preferred embodiment of the invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I) for the medical use(s) described herein, the 1 ,2,3-triazole-4-amine derivatives of general formula (I) optionally being in the form of said pharmaceutical composition, said medicament, or said pharmaceutical administration form, wherein the disease and/or condition is selected from the group consisting of pain, preferably neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia.
  • An even more preferred embodiment of the invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I) for the medical use(s) described herein, the 1 ,2,3-triazole-4- amine derivatives of general formula (I) optionally being in the form of said pharmaceutical composition, said medicament, or said pharmaceutical administration form, wherein the disease and/or condition is allodynia and/or hyperalgesia.
  • a most preferred embodiment of the invention relates to 1 ,2,3-triazole-4-amine derivatives of general formula (I) for the medical use(s) described herein, the 1 ,2,3-triazole-4-amine derivatives of general formula (I) optionally being in the form of said pharmaceutical composition, said medicament, or said pharmaceutical administration form, wherein the disease and/or condition is mechanical or thermal allodynia, preferably mechanical allodynia.
  • Another aspect of the present invention refers to a method for the prophylaxis and/or treatment of diarrhea, lipoprotein disorders, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, migraine, arthritis, hypertension, arrhythmia, ulcer, glaucoma, learning, memory and attention deficits, cognition disorders, neurodegenerative diseases, demyelinating diseases, addiction to drugs and chemical substances including ***e, amphetamine, ethanol and nicotine; tardive diskinesia, ischemic stroke, epilepsy, stroke, stress, cancer, psychotic conditions, in particular depression, anxiety or schizophrenia; inflammation or autoimmune diseases, for the treatment and prophylaxis of pain, especially neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia, the method comprising administering to the subject at least one compound of general formula (I) as described above and optionally at least one further active substance and/or optionally at least one auxiliary substance to the subject.
  • the method comprising administering to the subject at
  • a preferred embodiment of the invention relates to a method for the prophylaxis and/or treatment of pain, especially neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia, the method comprising administering to the subject at least one compound of general formula (I) as described above and optionally at least one further active substance and/or optionally at least one auxiliary substance to the subject.
  • a most preferred embodiment of the present invention relates to method for the prophylaxis and/or treatment of mechanical or thermal allodynia, preferably mechanical allodynia., the method comprising administering to the subject at least one compound of general formula (I) as described above and optionally at least one further active substance and/or optionally at least one auxiliary substance to the subject.
  • Medicaments according to the present invention may also be formulated into orally administrable compositions containing one or more physiologically compatible carriers or excipients, in solid or liquid form. These compositions may contain conventional ingredients such as binding agents, fillers, lubricants, and acceptable wetting agents.
  • the compositions may take any convenient form, such as tablets, pellets, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, or dry powdered forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or retarded release.
  • Solid oral compositions (which are preferred as are liquid ones) may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art.
  • the tablets may for example be prepared by wet or dry granulation and optionally coated according to the methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • the mentioned formulations will be prepared using standard methods such as those described or referred to in the Spanish and US Pharmacopeias and similar reference texts.
  • liquid oral forms for administration may also contain certain additives such as sweeteners, flavoring, preservatives, and emulsifying agents.
  • Non-aqueous liquid compositions for oral administration may also be formulated, containing edible oils. Such liquid compositions may be conveniently encapsulated in e.g., gelatin capsules in a unit dosage amount.
  • compositions of the present invention may also be administered topically or via a suppository.
  • the medicament according to the present invention may be in any form suitable for the application to humans and/or animals, preferably humans including infants, children and adults and can be produced by standard procedures known to those skilled in the art.
  • the composition of the medicament may vary depending on the route of administration.
  • the medicament of the present invention may for example be administered parentally in combination with conventional injectable liquid carriers, such as water or suitable alcohols.
  • conventional pharmaceutical excipients for injection such as stabilizing agents, solubilizing agents, and buffers, may be included in such injectable compositions.
  • These medicaments may for example be injected intramuscularly, intraperitoneally, or intravenously.
  • Solid oral compositions (which are preferred as are liquid ones) may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are conventional in the art.
  • the tablets may for example be prepared by wet or dry granulation and optionally coated according to the methods well known in normal pharmaceutical practice, in particular with an enteric coating.
  • the mentioned formulations will be prepared using standard methods such as those described or referred to in the Spanish and US Pharmacopeias and similar reference texts.
  • Medicaments according to the present invention may also be formulated into orally administrable compositions containing one or more physiologically compatible carriers or excipients, in solid or liquid form.
  • These compositions may contain conventional ingredients such as binding agents, fillers, lubricants, and acceptable wetting agents.
  • the compositions may take any convenient form, such as tablets, pellets, capsules, lozenges, aqueous or oily solutions, suspensions, emulsions, or dry powdered forms suitable for reconstitution with water or other suitable liquid medium before use, for immediate or retarded release.
  • the liquid oral forms for administration may also contain certain additives such as sweeteners, flavoring, preservatives, and emulsifying agents.
  • Non-aqueous liquid compositions for oral administration may also be formulated, containing edible oils. Such liquid compositions may be conveniently encapsulated in e.g., gelatin capsules in a unit dosage amount. The compositions of the present invention may also be administered topically or via a suppository.
  • the daily dosage for humans and animals may vary depending on factors that have their basis in the respective species or other factors, such as age, sex, weight or degree of illness and so forth.
  • the daily dosage for humans may preferably be in the range froml to 2000, preferably 1 to 1500, more preferably 1 to 1000 milligrams of active substance to be administered during one or several intakes per day.
  • the present invention is illustrated below with the aid of examples. These illustrations are given solely by way of example and do not limit the general spirit of the present invention.
  • a schlenk tube was charged with fert-butyl 2-(4-acetylpiperazin-1-yl)ethylcarbamate (5.39 g, 19.9 mmol, 1 equiv.), CuS0 4 -5H 2 0 (532 mg, 1.98 mmol, 0.1 equiv.), K 3 P0 4 (8.43 g, 40 mmol, 2 equiv.) and 1 ,10-phenanthroline (715 mg, 4 mmol, 0.2 equiv.), evacuated and backfilled with argon.
  • Examples 2-51 were prepared following the same method as described in example 1 :
  • reaction mixture was then diluted with CH 2 CI 2 , washed with 3% aq. HCI (three times), saturated aq. NaHC0 3 (three times) and finally with saturated aq. NaCI.
  • the combined organic fractions were dried over MgS0 4 and the solvent removed under reduced pressure after filtration to afford A/-(1-(1-adamantyl)-1 H-1 ,2,3-triazol-4-yl)-A/-(2- morpholinoethyl)cyclopropanecarboxamide (101 mg, 83%) as a colourless oil.
  • the compound was prepared as hydrochloride salt following the method described in example 1.
  • Example 60 was prepared following the above described method
  • Example 61 Synthesis of 1-(3,4-dichlorophenyl)-W-(2-morpholinoethyl)-/V-propyl-1 H- 1 ,2,3-triazol-4-amine hydroch
  • Example 68 Synthesis of 1-(1-(3,4-dichlorophenyl)-1H-1 ,2,3-triazol-4-yl)-1-(2- morpholinoethyl)-3-propylthiourea hydrochloride
  • guinea pig brains are homogenized in 10 vols, (w/v) of Tris-HCI 50 mM 0.32 M sucrose, pH 7.4, with a Kinematica Polytron PT 3000 at 15000 r.p.m. for 30 s.
  • the homogenate is centrifuged at 1000g for 10 min at 4 Degrees C and the supernatants collected and centrifuged again at 48000g for 15 min at 4 Degrees C.
  • the pellet is resuspended in 10 volumes of Tris-HCI buffer (50 mM, pH 7.4), incubated at 37 Degrees C for 30 min, and centrifuged at 48000g for 20 min at 4 Degrees C. Following this, the pellet is resuspended in fresh Tris-HCI buffer (50 mM, pH 7.4) and stored on ice until use.
  • Tris-HCI buffer 50 mM, pH 7.4
  • Each assay tube contains 10 pL of [ 3 H](+)-pentazocine (final concentration of 0.5 nM), 900 pL of the tissue suspension to a final assay volume of 1 ml. and a final tissue concentration of approximately 30 mg tissue net weight/mL. Non-specific binding is defined by addition of a final concentration of 1 ⁇ haloperidol. All tubes are incubated at 37 Degrees C for 150 min before termination of the reaction by rapid filtration over Schleicher and Schuell GF 3362 glass fibre filters [previously soaked in a solution of 0,5 percent polyethylenimine for at least 1 h]. Filters are then washed four times with 4 mL of cold Tris-HCI buffer (50 mM, pH 7.4).
  • Binding studies for sigma2-receptor are performed as described ( adesca et al., 1991 ) with some modifications.
  • brains from sigma receptor type I (sigmal ) knockout mice are homogenized in a volume of 10 mUg tissue net weight of ice-cold 10 mM Tris-HCI, pH 7.4, containing 320 mM sucrose (Tris-sucrose buffer) with a Potter-Elvehjem homogenizer (10 strokes at 500 r.p.m.) The homogenates are then centrifuged at 1000g for 10 min at 4 degrees centigrade, and the supernatants are saved.
  • the pellets are resuspended by vortexing in 2 mUg ice-cold Tris-sucrose buffer and centrifuged again at 1000g for 10 min.
  • the combined 1000g supernatants are centrifuged at 31000g for 15 min at 4 Degrees C.
  • the pellets are resuspended by vortexing in 3 mUg 10 mM Tris-HCI, pH 7.4, and the suspension is kept at 25 Degrees C for 15 min.
  • the pellets are resuspended by gentle Potter Elvehjem homogenization to a volume of 1 .53 mUg in 10 mM Tris-HCI pH 7.4.
  • the assay tubes contain 10, ⁇ _ of [ 3 H]-DTG (final concentration of 3 nM), 400 ⁇ _ of the tissue suspension (5.3 mUg in 50 mM Tris-HCI, pH 8.0) to a final assay volume of 0.5 mL.
  • Non-specific binding is defined by addition of a final concentration of 1 ⁇ haloperidol.
  • All tubes are incubated at 25 Degrees C for 120 min before termination of the reaction by rapid filtration over Schleicher and Schuell GF 3362 glass fibre filters [previously soaked in a solution of 0,5 percent polyethylenimine for at least 1 h]. Filters are washed three times with 5 mL volumes of cold Tris-HCI buffer (10 mM, pH 8.0).
  • Brain membrane preparation and binding assays for the ⁇ 1 -receptor were performed as described (DeHaven-Hudkins, D. L, L.C. Fleissner, and F. Y. Ford-Rice, 1992, Characterization of the binding of [ 3 H](+)pentazocine to ⁇ recognition sites in guinea pig brain, Eur. J. Pharmacol. 227, 371-378) with some modifications.
  • Guinea pig brains were homogenized in 10 vols, (w/v) of Tris-HCI 50 mM 0.32 M sucrose, pH 7.4, with a Kinematica Polytron PT 3000 at 15000 r.p.m. for 30 s.
  • the homogenate was centrifuged at 1000g for 10 min at 4°C and the supernatants collected and centrifuged again at 48000g for 15 min at 4°C.
  • the pellet was resuspended in 10 volumes of Tris-HCI buffer (50 mM, pH 7.4), incubated at 37°C for 30 min, and centrifuged at 48000g for 20 min at 4°C. Following this, the pellet was re-suspended in fresh Tris-HCI buffer (50 mM, pH 7.4) and stored on ice until use.
  • the radioligand used was [ 3 H]-(+)-pentazocine at 5.0 nM and the final volume was 200 ⁇ .
  • the incubation was initiated with the addition of 100 ⁇ of membrane at a final tissue concentration of approximately 5 mg tissue net weight/mL and the incubation time was 150 m. at 37 °C.
  • the membranes were collected onto pretreated glass fiber filterplate (MultiScreen-FC, Millipore), with polyethylenimine 0.1 %.
  • Microplates were allowed to set for several hours and then quantified by liquid scintillation spectrophotometry (1450 Microbeta, Wallac). Nonspecific binding was determined with 1 ⁇ haloperidol.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP14700430.3A 2013-01-07 2014-01-07 1,2,3-triazol-4-amin-derivate zur behandlung von erkrankungen und störungen im zusammenhang mit sigma-rezeptoren Not-in-force EP2941424B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP14700430.3A EP2941424B1 (de) 2013-01-07 2014-01-07 1,2,3-triazol-4-amin-derivate zur behandlung von erkrankungen und störungen im zusammenhang mit sigma-rezeptoren

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13382002.7A EP2752411A1 (de) 2013-01-07 2013-01-07 1,2,3-Triazol-4-amin-Derivate zur Behandlung von Erkrankungen und Störungen im Zusammenhang mit Sigma-Rezeptoren
EP14700430.3A EP2941424B1 (de) 2013-01-07 2014-01-07 1,2,3-triazol-4-amin-derivate zur behandlung von erkrankungen und störungen im zusammenhang mit sigma-rezeptoren
PCT/EP2014/000012 WO2014106622A1 (en) 2013-01-07 2014-01-07 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders

Publications (2)

Publication Number Publication Date
EP2941424A1 true EP2941424A1 (de) 2015-11-11
EP2941424B1 EP2941424B1 (de) 2017-07-05

Family

ID=47603514

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13382002.7A Withdrawn EP2752411A1 (de) 2013-01-07 2013-01-07 1,2,3-Triazol-4-amin-Derivate zur Behandlung von Erkrankungen und Störungen im Zusammenhang mit Sigma-Rezeptoren
EP14700430.3A Not-in-force EP2941424B1 (de) 2013-01-07 2014-01-07 1,2,3-triazol-4-amin-derivate zur behandlung von erkrankungen und störungen im zusammenhang mit sigma-rezeptoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP13382002.7A Withdrawn EP2752411A1 (de) 2013-01-07 2013-01-07 1,2,3-Triazol-4-amin-Derivate zur Behandlung von Erkrankungen und Störungen im Zusammenhang mit Sigma-Rezeptoren

Country Status (10)

Country Link
US (1) US9611229B2 (de)
EP (2) EP2752411A1 (de)
JP (1) JP6370803B2 (de)
CN (1) CN104903309B (de)
CA (1) CA2893472A1 (de)
ES (1) ES2642403T3 (de)
HK (1) HK1216641A1 (de)
MX (1) MX2015008733A (de)
PT (1) PT2941424T (de)
WO (1) WO2014106622A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9718789B2 (en) * 2015-01-30 2017-08-01 Neurocrine Biosciences, Inc. Substituted triazoles and methods relating thereto
EP3402779A1 (de) * 2016-01-15 2018-11-21 Esteve Pharmaceuticals, S.A. 3-ethyl-3-phenylazepanderivate mit einer multimodalen aktivität gegen schmerzen
CN106117154B (zh) * 2016-06-30 2018-12-14 昆明理工大学 一种邻芳氧基-1,4-二芳基-1,2,3-三氮唑衍生物及其制备方法和应用
KR20180036318A (ko) * 2016-09-30 2018-04-09 경북대학교 산학협력단 2-아미노-2-(1-도데실-1h-1,2,3-트리아졸-4-일)프로판-1,3-디올 유도체를 유효성분으로 포함하는 퇴행성 신경질환 및 우울증 예방 또는 치료용 약학적 조성물
CN112386679B (zh) * 2020-11-18 2023-05-30 徐州医科大学 一种包载sigma-1受体的外泌体在制备抗抑郁药物中的应用
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343497A4 (de) * 2000-11-02 2005-01-26 K And K Biosciences Inc $g(D)?2,-1,2,3-TRIAZOLIN-ANTIKONVULSIVA UND IHRE AKTIVEN METABOLITENANALOGA, DIE AMINOALKYLPYRIDINE, SIND EXZITATORISCHE AMINOSÄUREANTAGONISTEN UND ANTIISCHÄMISCHE VERBINDUNGEN ZUR VERWENDUNG BEI DER BEHANDLUNG DER APOPLEXIE-BEDINGTEN ZEREBRALEN ISCHÄMIE
EP1634873A1 (de) 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Sigmarezeptor-Inhibitoren
EP1829869A1 (de) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. 4,5,6,7-Tetrahydrobenzo[b]thiophenderivative und ihre Verwendung als sigma Rezeptor-Liganden
EP1829867A1 (de) * 2006-03-03 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Gegenüber dem Sigmarezeptor pharmazeutisch aktive Imidazolverbindungen
EP1847542A1 (de) 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran]- oder Spiro[benzofuran]derivative als Sigma Rezeptor Antagonisten
EP1921073A1 (de) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole als Sigma Rezeptoren Hemmstoffe
EP1921071A1 (de) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3-Triazol Derivate als Sigma Rezeptoren Hemmstoffe
EP2070933A1 (de) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Trizyklische triazolische Verbindungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2014106622A1 *

Also Published As

Publication number Publication date
WO2014106622A1 (en) 2014-07-10
ES2642403T3 (es) 2017-11-16
CN104903309B (zh) 2017-12-19
US20150353510A1 (en) 2015-12-10
CN104903309A (zh) 2015-09-09
MX2015008733A (es) 2015-11-16
JP6370803B2 (ja) 2018-08-08
US9611229B2 (en) 2017-04-04
CA2893472A1 (en) 2014-07-10
JP2016506415A (ja) 2016-03-03
HK1216641A1 (zh) 2016-11-25
PT2941424T (pt) 2017-10-09
EP2752411A1 (de) 2014-07-09
EP2941424B1 (de) 2017-07-05

Similar Documents

Publication Publication Date Title
EP1829869A1 (de) 4,5,6,7-Tetrahydrobenzo[b]thiophenderivative und ihre Verwendung als sigma Rezeptor-Liganden
EP2941424B1 (de) 1,2,3-triazol-4-amin-derivate zur behandlung von erkrankungen und störungen im zusammenhang mit sigma-rezeptoren
US20100184759A1 (en) Pyrano-pyrazole-amines
CA2556568A1 (en) Substituted pyrazoline compounds for reducing triglycerides in blood
EP3288941B1 (de) Spiro-isochinolin-3,4'-piperidin-verbindungen mit aktivität gegen schmerzen
US9271959B2 (en) Bicyclic tetrahydropyrrole compounds
EP2870145B1 (de) Indenderivate, ihre herstellung und verwendung als arzneimittel
EP2920174A1 (de) Substituierte pyrazol[3,4-d]pyrimidinverbindungen, deren herstellung und verwendung als sigma-rezeptorliganden
EP3365338B1 (de) Substituierte morpholinderivate mit aktivität gegen schmerzen
WO2013124341A1 (en) Substituted pyrazolo[1,5-a]pyridines, their preparation and use as medicaments
US20190002475A1 (en) Oxa-diazaspiro compounds having activity against pain
US10183918B2 (en) Oxa-azaspiro compounds having activity against pain
EP1996548B1 (de) Sigma-rezeptor-liganden

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20150730

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20160519

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1216641

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20170103BHEP

Ipc: C07D 249/04 20060101ALI20170103BHEP

Ipc: A61K 31/5377 20060101ALI20170103BHEP

Ipc: A61P 19/00 20060101ALI20170103BHEP

Ipc: A61P 9/00 20060101ALI20170103BHEP

Ipc: C07F 7/10 20060101ALI20170103BHEP

Ipc: A61P 1/00 20060101ALI20170103BHEP

Ipc: C07D 249/06 20060101ALI20170103BHEP

Ipc: A61P 25/00 20060101ALI20170103BHEP

Ipc: A61K 31/496 20060101ALI20170103BHEP

Ipc: A61P 3/00 20060101ALI20170103BHEP

Ipc: A61K 31/4192 20060101ALI20170103BHEP

Ipc: A61K 31/4439 20060101ALI20170103BHEP

Ipc: C07D 401/12 20060101AFI20170103BHEP

Ipc: A61P 5/00 20060101ALI20170103BHEP

Ipc: C07D 295/185 20060101ALI20170103BHEP

INTG Intention to grant announced

Effective date: 20170126

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 906522

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170715

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602014011464

Country of ref document: DE

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2941424

Country of ref document: PT

Date of ref document: 20171009

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20171003

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ROSENICH PAUL; KUENSCH JOACHIM PATENTBUERO PAU, LI

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2642403

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20171116

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171005

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171105

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171005

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20170402626

Country of ref document: GR

Effective date: 20180309

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602014011464

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1216641

Country of ref document: HK

26N No opposition filed

Effective date: 20180406

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

REG Reference to a national code

Ref country code: ES

Ref legal event code: PC2A

Owner name: ESTEVE PHARMACEUTICALS, S.A.

Effective date: 20181022

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: ESTEVE PHARMACEUTICALS, S.A., ES

Free format text: FORMER OWNER: LABORATORIOS DEL DR. ESTEVE, S.A., ES

REG Reference to a national code

Ref country code: LU

Ref legal event code: HC

Owner name: ESTEVE PHARMACEUTICALS, S.A.; ES

Free format text: FORMER OWNER: LABORATORIOS DEL DR. ESTEVE, S.A.

Effective date: 20190313

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 906522

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170705

REG Reference to a national code

Ref country code: NL

Ref legal event code: HC

Owner name: ESTEVE PHARMACEUTICALS, S.A.; ES

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME; FORMER OWNER NAME: LABORATORIOS DEL. DR. ESTEVE, S.A.

Effective date: 20190301

REG Reference to a national code

Ref country code: BE

Ref legal event code: HC

Owner name: ESTEVE PHARMACEUTICALS, S.A.; ES

Free format text: DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGEMENT DE NOM DU PROPRIETAIRE; FORMER OWNER NAME: LABORATORIOS DEL DR. ESTEVE, S.A.

Effective date: 20190429

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602014011464

Country of ref document: DE

Representative=s name: DEHMEL & BETTENHAUSEN PATENTANWAELTE PARTMBB, DE

Ref country code: DE

Ref legal event code: R082

Ref document number: 602014011464

Country of ref document: DE

Representative=s name: ZACCO PATENTANWALTS- UND RECHTSANWALTSGESELLSC, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 602014011464

Country of ref document: DE

Owner name: ESTEVE PHARMACEUTICALS, S.A., ES

Free format text: FORMER OWNER: LABORATORIOS DEL DR. ESTEVE S.A., BARCELONA, ES

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180107

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20191230

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20191230

Year of fee payment: 7

Ref country code: BE

Payment date: 20191230

Year of fee payment: 7

Ref country code: GR

Payment date: 20191230

Year of fee payment: 7

Ref country code: FR

Payment date: 20191226

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20191230

Year of fee payment: 7

Ref country code: DE

Payment date: 20191218

Year of fee payment: 7

Ref country code: NL

Payment date: 20200102

Year of fee payment: 7

Ref country code: AT

Payment date: 20191230

Year of fee payment: 7

Ref country code: ES

Payment date: 20200203

Year of fee payment: 7

Ref country code: IT

Payment date: 20200117

Year of fee payment: 7

Ref country code: GB

Payment date: 20191231

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20200106

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20140107

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20170705

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170705

REG Reference to a national code

Ref country code: CH

Ref legal event code: PCAR

Free format text: NEW ADDRESS: ROTENBODENSTRASSE 12, 9497 TRIESENBERG (LI)

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 602014011464

Country of ref document: DE

Representative=s name: DEHMEL & BETTENHAUSEN PATENTANWAELTE PARTMBB, DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602014011464

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: NL

Ref legal event code: MM

Effective date: 20210201

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 906522

Country of ref document: AT

Kind code of ref document: T

Effective date: 20210107

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20210107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210107

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20210131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210107

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210201

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210805

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210131

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210707

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210107

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210803

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210107

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220413

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210107

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210108

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20210131